Relationship Between Great Toe Strength And Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Launched by UNIVERSITY OF FLORIDA · Jun 6, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at the strength of the great toe and how it relates to symptoms of chemotherapy-induced peripheral neuropathy (CIPN), a condition that can cause nerve damage after cancer treatment. Researchers want to see if measuring great toe strength can help identify nerve issues in people who have CIPN as well as in healthy individuals. Participants will use a special device called ToeScale to measure their toe strength, and will also answer some questionnaires and undergo balance and walking tests.

To be eligible for the study, you should be at least 18 years old and able to move your great toe on your own. If you have recently started chemotherapy and have been diagnosed with CIPN, you can participate in that group. However, some health conditions, like diabetes or arthritis, might prevent you from joining. Healthy individuals can also take part in the study if they are matched in age and gender with those in the CIPN group and do not have any health issues affecting their mobility. Remember, this study is not yet recruiting participants, but it aims to find ways to better understand and address the challenges faced by those experiencing CIPN.

Gender

ALL

Eligibility criteria

• Eligibility Criteria for Chemotherapy-Induced Peripheral Neuropathy (CIPN) group:
• Inclusion Criteria:
• • At least 18 years of old with the ability to independently raise and low (extend or flex) the great toe
• • Able to consent and complete questionnaires in English independently and have normal to corrected vision (self-reported)
• • Within 3 - 6 months of starting chemotherapy and a confirmed diagnosis of CIPN using the current clinical reference standard of Nerve conduction study.
• Exclusion Criteria:
• • Comorbidities including but not limited to diabetes, arthritis, hypertension, thyroid disease, and heart disease, . that have been reported to be associated with the incidence of peripheral neuropathy and/or progression of CIPN.
• • Toe deformities or impairments not caused by CIPN (including but not limited to hallux valgus/varus, hallux limitus, hallux rigidus, hammer toe deformity, claw toe, bunions, webbed toes)
• • Self-reported impairment or impact on the strength of the foot, ankle, and/or great toe due to past medical or surgical history.
• • Eligibility Criteria for Healthy Control group: The participants recruited for this group will be age- and sex- matched to the CIPN group
• * Inclusion Criteria:
• • At least 18 years of old with the ability to independently raise and low (extend or flex) the great toe
• • Able to consent and complete questionnaires in English independently and have normal to corrected vision (self-reported)
• • No known health conditions that have been reported to be associated with different impairements in mobility, balance, and muscle strength (particularly in the lower extremity)